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A B S T R A C T   
Introduction: Physiotherapy may alleviate many multiple sclerosis (MS) symptoms, yet very little is known about physiotherapy accessibility and possible barriers in 
persons with MS (pwMS). We therefore aimed to elucidate physiotherapy use and possible access-barriers using data from 1493 pwMS from the Swiss Multiple 
Sclerosis Registry (SMSR), a patient-centered, longitudinal, observational MS study. 
Methods: We used data of the SMSR to investigate the question at hand in a multivariable logistic regression model with regularly receiving physiotherapy (yes/no) as 
the outcome. Potential explanatory variables were investigated following an AIC-driven model selection approach and consisted of a priori specified socio- 
demographic variables, health status, and personal or social mobility variables. As a last step, the impact of physiotherapist supply on regular use was assessed 
in the final model. Missing data were handled by multiple imputation (main analysis), and complete case sensitivity analyses were performed. 
Results: The main analysis included 1493 participants. In the multivariable logistic regression, positive associations were found between the use of physiotherapy and 
the following variables: having a primary-progressive MS (Odds Ratio (OR) [95% Confidence Intervals] 1.97 [1.18; 3.29]), being more severely impaired (EDSS 4-6.5 
OR 1.84 [1.16; 2.91]), higher number of current symptoms (1 OR 3.31 [1.63; 6.74], 2-3 OR 3.43 [1.8; 6.53], 4-5 OR 4.44 [2.28; 8.66], 6-7 OR 4.06 [1.90; 8.70], 8-9 
OR 3.87 [1.71; 8.75], being on disability pension (OR 1.75 [1.24; 2.46], or having applied for it OR 2.25 [1.31; 3.85]), having gait problems (OR 1.58 [1.11; 2.23]), 
having been in a rehabilitation clinic in the past 12 months (OR 4.43 [2.17; 9.03]), and currently being on disease-modifying treatment (OR 1.61 [1.12; 2.31]). 
Negative associations were found for a higher quality of life (OR 0.92 [0.85; 0.98]), working more than 80% (OR 0.47 [0.30; 0.75]) and being from the French 
language region (OR 0.66 [0.47; 0.94]). No association between physiotherapist supply and regular physiotherapy use was detected. 
Discussion: In a large, Swiss-based MS population, little evidence for socio-demographic barriers to physical therapy was found. Physiotherapy uptake was higher 
among pwMS with more impairments, lower health-related quality of life, or who have been discharged recently from inpatient rehabilitation. The uptake differences 
by language region warrant further investigations.   
1. Background 
Multiple sclerosis (MS) is a chronic inflammatory and degenerative 
disease of the central nervous system, with onset in early adulthood, 
affecting approximately 15,000 people in Switzerland and over 2 million 
worldwide (Kaufmann et al., 2019; Vos et al., 2016). 
While disease-modifying treatments (DMT) are essential to minimize 
axonal damage and loss, as well as the relapse rate, there is currently still 
no curative treatment for MS. In addition, drugs that ameliorate clinical 
symptoms are sparse (Toosy et al., 2014). Therefore, existing symptoms 
must be managed with symptomatic forms of therapy such as physical 
and occupational therapies. 
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Physiotherapy is recommended for the treatment of MS, since there 
is strong evidence that it helps to improve quality of life (QoL) as well as 
to maintain mobility (Alphonsus et al., 2019; Khan and Amatya, 2017). 
Furthermore, physiotherapy alleviates gait problems (Henze et al., 
2017; Khan and Amatya, 2017; Wiles et al., 2001) and reduces bladder 
problems, in particular through pelvic floor exercises (Block et al., 2015; 
Henze, 2004; Henze et al., 2018a; Kesselring and Beer, 2005). Moreover, 
there is some evidence that physiotherapy may improve balance (Khan 
and Amatya, 2017; Paltamaa et al., 2012; Wiles et al., 2001), ameliorate 
spasticity (Henze, 2004), and reduce pain (in particular shoulder, neck, 
joint and back pain) (Henze, 2004). In addition, there is strong evidence 
for physiotherapy being able to reduce fatigue (Henze et al., 2018b; 
Kesselring and Beer, 2005; Khan and Amatya, 2017). All these symptoms 
have been shown to reduce QoL and are all common in people with MS 
(Barin et al., 2018). 
Despite proven benefits, uptake of physiotherapy is not universal in 
Switzerland and other countries. As shown by an earlier study, as many 
as 43% of the participants in the Swiss MS Registry reported to receive 
physiotherapy on a regular basis. (Barin et al., 2019). Studies to inves-
tigate possible reasons for limited physiotherapy access or uptake have 
been performed in other countries, but not in Switzerland. For example, 
Campbell et al. reported that physiotherapy access for pwMS is mostly 
hindered by mobility, fatigue, continence and transport issues and the 
need of attendance (Campbell et al., 2017). Additionally, distance to 
travel, pain, difficulty with wheelchair transfers, poor availability of 
physiotherapy-services, work and family commitments and depression, 
had been reported as potential barriers (Campbell et al., 2017). By 
contrast, Finlayson et al. further reported that living in an urban or 
suburban community, a deteriorating MS status, experiencing problems 
with spasticity, having transfer difficulties in the living environment, 
being hospitalized in the past 6 months, and seeing a family physician, 
were positively associated with recent use of physiotherapy services 
(Finlayson et al., 2010). Furthermore, Milivojevic et al. found, that 
pwMS who used rehabilitation had higher levels of impairment 
compared to those without (Milivojević et al., 2013). 
However, there are also notable differences between the health 
systems included in these earlier studies and the Swiss setting. 
Switzerland has a mandatory health insurance system with nearly uni-
versal access to care, but high out-of-pocket costs and deductibles 
(Osborn et al., 2016). Physiotherapy is reimbursed by mandatory health 
insurance, if it is prescribed by a physician. However, prescriptions are 
usually limited to 9 sessions after which a new prescription is necessary. 
This can be renewed up to a total of 36 sessions yearly. Severely affected 
patients may receive long-term treatment over many years. For such 
long-term treatments, cost approval by the health insurance is required. 
Given the knowledge gaps about care access barriers for physio-
therapy in Switzerland, our objective was to identify factors that hinder 
or facilitate the use of physiotherapy. Furthermore, we aimed to inves-
tigate whether the availability of physiotherapists has an effect on 
physiotherapy use. 
2. Methods 
2.1. Participants and data analysis 
We analyzed data from the Swiss Multiple Sclerosis Registry (SMSR), 
which also assessed the use of physiotherapy in persons with MS. The 
SMSR is a prospective, observational, patient-centered, ongoing study 
including adults with MS living in Switzerland. This study obtains data 
directly from the participants with MS by online and paper question-
naires, that is, information is based on self-reports. To ensure disease 
status, participants are required to submit a diagnosis confirmation fil-
led out by their treating physician. Detailed information on study pop-
ulation and recruitment procedures have been published elsewhere 
(Puhan et al., 2018; Steinemann et al., 2018). The data used for this 
project are cross-sectional and based on the first questionnaire patients 
complete to enter the study (baseline questionnaire), assessed between 
June 2016 and April 2019. 
The Swiss Multiple Sclerosis Registry has been approved by the 
Ethics Committee of the Canton of Zurich (PB-2016-00,894), including 
the use of the registry data for the present study (KEK 2019-01027). 
Written informed consent has been obtained from all SMSR partici-
pants (Steinemann et al., 2018). 
To acquire a quantitative measure of physiotherapy supply, a proxy 
for physiotherapy availability, we used the ZIP codes of the 4057 
physiotherapists and clinics who reported offering general physio-
therapy and were registered on the Physioswiss website (https://www. 
physioswiss.ch/de/practices). We then used population count data from 
the Federal Statistical Office to calculate the number of therapists per 
10’000 inhabitants in each ZIP code area. 
2.2. Statistical analysis 
The outcome of interest was, whether pwMS “regularly used phys-
iotherapy” (wording in questionnaire). In Switzerland, physiotherapy 
for pwMS is mainly provided in dedicated physiotherapy practices, but 
to some extent also as home-based physiotherapy or in out-patient fa-
cilities of clinics. The groups with and without physiotherapy were 
compared descriptively by use of means for continuous and percentages 
for categorical variables. Moreover, to identify factors associated with 
physiotherapy use, a multivariable logistic regression model was built 
following an AIC-driven model selection algorithm with physiotherapy 
use as outcome. The model was built as follows: 
First, the following variables were defined as confounders: sex, age, 
MS type, an EDSS proxy measure based on self-reported walking dis-
tances (0-3.5; 4-6.5; 7-9.5) (Kaufmann et al., 2020), education level and 
smoking. These variables were included as fixed variables in all fitted 
models, since they correlate with disease severity and health-conscious 
behavior, as well as language region (representing cultural differences 
between parts of Switzerland), which influences healthcare use (Sup-
plementary Table 1). 
Second, a pre-specified set of variables of interest was defined, 
reflecting previously published, possible care access barriers: BMI, 
number of MS-symptoms, incontinence, gait problems, fatigue, pain, 
paralysis, weakness, balance problems, dizziness, work percent, 
disability pension, ability to drive, ability to use public transport, area 
type of residence, living situation, alcohol consumption and being in a 
wheelchair, all as categorical variables. In addition, time since diagnosis 
and health related quality of life as assessed by the EuroQol 5 Dimension 
instrument (EQ5D) were added as continuous variables. 
Third, a stepwise approach was followed by fitting a confounder- 
adjusted model adding only one variable of the predefined variable-set 
at a time. The model with the lowest Akaike information criterium 
(AIC) was then maintained and considered the new reference model in 
case of a decrease of 2 units or greater compared to the previous refer-
ence model (Faraway, 2002). Thereafter, the variable newly included in 
the model was removed from the set of potential variables and the 
process repeated, starting with the new reference model. The process 
ended once no variable further reduced the AIC by at least two units. 
Another description of this process can also be found in a previous study 
(Barin et al., 2019). 
Forth, using the final model from step 3, the following exploratory 
variables were examined following the same stepwise approach: citi-
zenship, changed nutrition, having any comorbidities, memory symp-
toms, sexual symptoms, epilepsy, gastrointestinal symptoms, tremor, 
spasms, paresthesia, dysphagia, language impairments, visual symp-
toms, depression, other symptoms not specified, disease-modifying 
treatment DMT, side effects, use of alternative medicine, lifestyle 
changes upon diagnosis, physical activity, having children and having 
been in a clinic for rehabilitation. 
To investigate any effect of physiotherapy availability on physio-
therapy use, the measure of supply (availability of physiotherapists per 
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10’000 inhabitants in a given region, categorized into quintiles) was 
added to the final, multivariable model. 
The model was developed on the basis of a dataset with imputation of 
missing values for variables of interest using multiple imputation by 
chained equations and the models run on the imputed dataset (Rubin, 
1996; White et al., 2011). As a sensitivity analysis, the results based on 
the imputed dataset were compared to the results in the complete case 
scenario. All statistical analyses were done using STATA version 16 
(Stata Corp. College Station, TX, USA). 
2.3. Results 
The patient selection process for this study is illustrated in Fig. 1. 
This study included 1493 participants, of which 693 [46.4%] regularly 
attended physiotherapy; 800 [53.6%] were not receiving physiotherapy. 
The overall median age was 48 years and 72.7% were females (not 
shown). Moreover, 3% had a clinically isolated syndrome (CIS), 10% 
primary progressive MS (PPMS), 68% relapsing-remitting MS (RRMS) 
and 17% secondary progressive MS (SPMS). 
As shown in Table 1 and Supplementary Table 2, several factors 
differed substantially between persons with and without uptake of 
physiotherapy. In particular, physiotherapy uptake was higher among 
persons with primary progressive MS, an EDSS proxy measure greater 
than 4, a longer time since diagnosis, a greater number of symptoms, and 
a lower health-related quality of life, as well as in persons who are not 
working or who are on disability pension. 
As displayed in Table 2, factors positively associated with use of 
physiotherapy were primary-progressive MS (OR 1.97 [1.18; 3.29]), 
being more severely impaired (EDSS 4-6.5 OR 1.84 [1.16; 2.91]), having 
a higher number of current symptoms (1 OR 3.31 [1.63; 6.74], 2-3 OR 
3.43 [1.80; 6.54], 4-5 OR 4.44 [2.28; 8.66], 6-7 OR 4.06 [1.90; 8.70], 8- 
9 OR 3.87 [1.71; 8.75]), being on disability pension (OR 1.75 [1.24; 
2.46], or having applied for disability pension OR 2.25 [1.31; 3.85]), 
Fig. 1. N, number; Study Flowchart. Displayed are the number of participants, 
also referred to as observations, and the number of exclusions due to missing 
values, leading to the number of cases included in the complete case analyses, 
which were used to build the model and later for the sensitivity analysis. 
Thereafter multiple imputation by chained equations was performed for the 
final analysis. The complete case models were also used for a sensi-
tivity analysis. 
Table 1 
Characteristics of persons with multiple sclerosis with and without regular use of 
physiotherapy.   
Physiotherapy   
Variable No  Yes  
N 800 53.6% 693 46.4% 
Sex (=Female) 607 75.9% 479 69.1% 
Age (mean) 43  52  
BMI (mean) 24.85  25.04  
Language region     
German 617 77.1% 557 81.2% 
French 148 18.5% 109 15.9% 
Italian 35 4.4% 20 2.9% 
Highest education level     
Up to mandatory school 30 3.9% 30 4.6% 
Apprenticeship 306 40.8% 294 44.7% 
Highschool 68 9.1% 58 8.8% 
Higher professional education 115 15.3% 108 16.4% 
University / University of applied sciences 231 30.8% 167 25.4% 
MS type     
CIS 39 5.0% 5 0.7% 
PPMS 37 4.7% 119 17.3% 
RRMS 648 82.9% 369 53.6% 
SPMS 58 7.4% 196 28.4% 
EDSS proxy     
0-3.5 673 84.1% 314 45.3% 
4-6.5 39 4.9% 174 25.1% 
7-9.5 12 1.5% 91 13.1% 
Time since diagnosis in years (mean) 8  13  
Number of current symptoms     
None 188 23.5% 14 2.0% 
1 119 14.9% 31 4.5% 
2-3 194 24.3% 94 13.6% 
4-5 133 16.6% 161 23.2% 
6-7 65 8.1% 129 18.6% 
8-9 46 5.8% 133 19.2% 
>10 55 6.9% 131 18.9% 
Disease modifying treatment (DMT) 595 77.8% 457 70.5% 
EQ5D-Index (mean) 0.86  0.68  
Working     
Not 205 26.8% 371 54.2% 
<50% 100 13.1% 120 17.5% 
50-80% 203 26.5% 137 20.0% 
>80% 258 33.7% 56 8.2% 
Disability pension     
No 593 77.2% 239 35.3% 
Yes 141 18.4% 373 55.0% 
Applied for 34 4.4% 66 9.7% 
Able to drive     
No 71 9.2% 175 25.5% 
Yes 632 81.7% 388 56.6% 
Yes, modified car 7 0.9% 67 9.8% 
No drivers license 64 8.3% 55 8.0% 
Able to use public transport 742 95.9% 538 78.9% 
Typology residential area     
Urban 474 60.2% 392 57.8% 
Sub-urban 190 24.1% 159 23.5% 
Rural 123 15.6% 127 18.7% 
Wheelchair 28 3.5% 215 31.0% 
Any comorbidities 187 23.4% 258 37.2% 
Having children 408 56.7% 437 69.8% 
Rehabilitation clinic stay in past 12 months 11 1.4% 132 19.0% 
BMI: Body Mass Index; CIS: Clinically isolated syndrome; EDSS: Expanded 
disability status scale; EQ5D: EuroQol 5 dimensions; MS: Multiple sclerosis; 
PPMS: Primary-progressive MS; RRMS: Relapsing-remitting MS; SPMS: 
Secondary-progressive MS. 
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gait problems (OR 1.58 [1.11; 2.23]), having been in a clinic for reha-
bilitation in the past 12 months (OR 4.43 [2.17; 9.03]), spasms (OR 2.05 
[1.46; 2.89]) and currently being on disease-modifying treatment (OR 
1.61 [1.12; 2.31]). A negative association was found for living outside 
the German-speaking part of Switzerland (French-speaking 0.66 [0.47; 
0.94]), a higher health-related quality of life (EQ5D OR 0.92 [0.85; 
0.98]) and working more than 80% (OR 0.47 [0.30; 0.75]). The sensi-
tivity analysis based on the complete case logistic regression yielded 
similar results as the main analysis. 
Furthermore, we studied whether the region-specific per-capita 
number of physiotherapists was associated with physiotherapy uptake 
by adding a quantitative measure of supply to the logistic regression 
presented in Table 2. This index of physiotherapy supply variable did 
not demonstrate an association with increased physiotherapy uptake. 
Moreover, the effect sizes for language region remained nearly un-
changed (results shown in Supplementary Table 3). 
3. Discussion 
By analyzing data from 1493 participants of the Swiss MS Registry, 
several factors were identified to be associated with an increased uptake 
of physiotherapy, namely a higher EDSS (as measured by the proxy), 
lower quality of life (EQ5D), having more MS-symptoms, being on 
disability pension, gait problems, spasms and having been in a clinic for 
rehabilitation in the past 12 months. By contrast, other variables pre-
viously implicated with care access barriers such as lower education or 
inability to drive did not reach statistical significance, or did not even 
enter the final model (e.g. ability to use public transport or degree of 
urbanity of home location). Furthermore, the supply of physiotherapists, 
expressed as number of physiotherapy providers per capita and divided 
into quintiles, was not associated with uptake. 
These findings suggest that the most important driver of physio-
therapy use is the impact on health-related quality of life by the disease 
(e.g., expressed the EQ-5D index) and the impairments (particularly gait 
problems or spasms). Nevertheless, physiotherapy use differed by lan-
guage regions, but those differences were independent of supply of 
physiotherapists per capita. Therefore, it could be speculated that not 
supply but referral and prescription practices of physicians may be 
somewhat different in non-German language regions of Switzerland. 
However, there is currently no evidence to support this or any alterna-
tive explanation for language region differences of physiotherapy up-
take in Switzerland. 
Our results indicate that an increase of symptoms and its conse-
quences in daily life are the main drivers for the uptake of physio-
therapy. Recent studies propose that exercise in MS may be viewed as a 
preventive and disease-modifying measure. It has been suggested that an 
early physiotherapy initiation, including strength and endurance exer-
cises, might change the course of MS. (Riemenschneider et al 2018, 
Dalgas et al 2019) However, our results do not support that the proposed 
paradigm shift has happened in Switzerland yet. 
Unlike in several other countries, little evidence could be found for 
systematic access-barriers on a population level. Therefore, this suggests 
that physiotherapy supply and access are in general quite good in 
Switzerland, which also corresponds to the view of many practitioners. 
However, access-barriers on an individual level may exist. For example, 
it is known for Switzerland that high out-of-pocket expenditures such as 
insurance deductibles can be prohibitive for accessing care. Because our 
data do not include insurance characteristics or income, we are unable 
to perform individual-level analyses into these aspects. Nonetheless, 
there are several other obstacles acting at the individual level that might 
have influenced our findings: lack of compatibility with vocational/ 
working duties, avoiding to be confronted with symptoms and the fear to 
be stigmatized, lack of awareness about preventive effects of physi-
otherapeutic treatment, fatigue and exhaustion in working individuals, 
but also the tendency to underreport minor physical deficits that might 
necessitate physiotherapeutic intervention and finally, the lack of 
availability of attendance are altogether personal and circumstantial 
variables that might impede a person with MS to claim for and to utilize 
physiotherapeutic supply. 
Comparisons with studies performed in different health care settings, 
such as the UK, are difficult. The health system differences may at least 
partially explain why there is little consistency between our findings and 
those of the survey conducted by Campbell et al. (2017). For example, 
we did not find any evidence in support of lack of mobility, fatigue, 
Table 2 
Confounder adjusted logistic regression model for the full sample to identify 
factors associated with physiotherapy use in persons with multiple sclerosis. 
Effect sizes that reached statistical significance (p<0.05) are indicated in bold. 
(A graph with depiction of the confidence intervals can be found in the appendix 
as supplementary Fig. 1)    
Physiotherapy [=Yes] 
Variable OR CI [95%] 
Sex (Female) 1.16 [0.83; 1.63] 
Age 1.05 [0.98; 1.12] 
MS type   
CIS 0.59 [0.21; 1.65] 
PPMS 1.97 [1.18; 3.29] 
RRMS ref.  
SPMS 1.23 [0.77; 1.96] 
EDSS proxy   
0-3.5 ref.  
4-6.5 1.84 [1.16; 2.91] 
7-9.5 1.77 [0.77; 4.06] 
Highest education level   
Up to mandatory school 0.75 [0.38; 1.47] 
Apprenticeship ref.  
Highschool 0.89 [0.53; 1.49] 
Higher professional education 1.33 [0.88; 2.01] 
University / University of applied sciences 1.20 [0.86; 1.69] 
Language region   
German ref.  
French 0.66 [0.47; 0.94] 
Italian 0.61 [0.3; 1.25] 
Smoker   
Never ref.  
Former 1.25 [0.92; 1.71] 
Current 0.96 [0.67; 1.37] 
EQ5D-index   
(per index point increase) 0.92 [0.85; 0.98] 
Number of symptoms   
None ref.  
1 3.31 [1.63; 6.74] 
2-3 3.43 [1.8; 6.53] 
4-5 4.44 [2.28; 8.66] 
6-7 4.06 [1.9; 8.7] 
8-9 3.87 [1.71; 8.75] 
>10 1.86 [0.77; 4.51] 
Working   
Not ref.  
<50% 1.16 [0.76; 1.76] 
50-80% 0.92 [0.64; 1.34] 
>80% 0.47 [0.3; 0.75] 
Disability pension   
No ref.  
Yes 1.75 [1.24; 2.46] 
Applied for 2.25 [1.31; 3.85] 
Gait problems 1.58 [1.11; 2.23] 
Able to drive   
No ref.  
Yes 0.81 [0.53; 1.22] 
Yes modified Car 2.13 [0.83; 5.44] 
No driver’s license 0.78 [0.44; 1.39] 
Pain 1.33 [0.95; 1.88] 
Rehabilitation clinic 4.43 [2.17; 9.03] 
Spasms 2.05 [1.46; 2.89] 
Disease-modifying treatment 1.61 [1.12; 2.31] 
Observations  1493 
CIS: Clinically isolated syndrome; EDSS: Expanded disability status scale; EQ5D: 
EuroQol 5 dimensions; MS: Multiple sclerosis; PPMS: Primary-progressive MS; 
RRMS: Relapsing-remitting MS; SPMS: Secondary-progressive MS. 
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continence issues, transport issues or the patient needing someone to go 
with them hindering physiotherapy use on a population level. This could 
be due to two factors: One being that the UK study was conducted in 
persons with PPMS, while our study included all MS types, most of 
which with a RRMS. The other being that the UK study was a ques-
tionnaire specifically asking pwMS about access-barriers, thus assessing 
this topic more on an individual level, while we were investigating 
access-barriers on a population level. 
Notable strengths of our study are: Its comparatively large sample 
size (Calabrese et al., 2017; Campbell et al., 2017) and the inclusion of 
persons across the full MS disease spectrum (including newly diagnosed 
and persons with progressive MS). This was enabled by the provision of 
paper and online questionnaires in three national languages, as well as 
the broad support and communication of the Swiss Multiple Sclerosis 
Society. Furthermore, we were able to cover a comprehensive battery of 
variables on geographic, socio-demographic, and MS-related factors 
(Puhan et al., 2018). However, some limitations need to be mentioned, 
namely a lack of information on participants financial situations and 
health insurance status, as well as the fact that all the variables were 
self-reported and therefore prone to the known biases (e.g. recall or 
underreporting bias). While certain variables intuitively appear to be 
closely related, no problems of multicollinearity were detected. 
Furthermore, in the analysis of physiotherapist density, we were unable 
to consider the specialty of physiotherapists. 
To summarize, our study has found little evidence for physiotherapy 
access-barriers on a population level in people with MS living in 
Switzerland, a setting with universal access to health care. 
Accordingly, use of physiotherapy was primarily driven by health 
status, namely pwMS with a higher disability and lower health-related 
quality of life. Furthermore, having been in a rehabilitation clinic in 
the past 12 months also stood out as a driving factor for use of out- 
patient physiotherapy. Physiotherapy is a standard treatment in inpa-
tient rehabilitation. Upon discharge, persons with MS are often directly 
referred to physiotherapists and advised to continue the exercise pro-
grams. There were also indications of physiotherapy uptake differences 
between the German and the French and Italian language regions. 
Whether these regional differences will be confirmed, and if these are 
rooted in cultural aspects, different collaboration and referral models 
between neurologists and physiotherapists, or other as of yet unknown 
factors warrants further investigation. 
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